Garry Neil
2022
In 2022, Garry Neil earned a total compensation of $1.3M as Chief Executive Officer, President, Chairman of the Board and principal executive officer at Avalo Therapeutics, a 8% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $133,000 |
|---|---|
| Option Awards | $730,928 |
| Salary | $468,900 |
| Total | $1,332,828 |
Neil received $730.9K in option awards, accounting for 55% of the total pay in 2022.
Neil also received $133K in non-equity incentive plan and $468.9K in salary.
Rankings
In 2022, Garry Neil's compensation ranked 2,475th out of 5,760 executives tracked by ExecPay. In other words, Neil earned more than 57.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,475 out of 5,760 | 57th |
Division Manufacturing | 1,360 out of 3,136 | 57th |
Major group Chemicals And Allied Products | 614 out of 1,422 | 57th |
Industry group Drugs | 568 out of 1,323 | 57th |
Industry Pharmaceutical Preparations | 407 out of 969 | 58th |
Source: SEC filing on October 19, 2023.
Neil's colleagues
We found three more compensation records of executives who worked with Garry Neil at Avalo Therapeutics in 2022.